Form 8-K

8-K — ANAVEX LIFE SCIENCES CORP.

Accession: 0001731122-26-000678

Filed: 2026-05-06

Period: 2026-04-30

CIK: 0001314052

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — e7613_8-k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7613_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7613_8-k.htm · Sequence: 1

false

0001314052

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April

30, 2026

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada

001-37606

98-0608404

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

630 5th Avenue, 20th Floor, New York, NY

USA 10111

(Address of principal executive offices) (Zip Code)

1-844-689-3939

Registrant’s telephone number, including area

code

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, par value $0.001 per share

AVXL

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Termination of Chief Executive Officer

On April 30, 2026, a special committee (the “Special

Committee”) composed of independent directors of the Board of Directors (the “Board”) of Anavex Life Sciences Corp.

(the “Company”) terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for

Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated),

effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy. The

Special Committee has also requested that Dr. Missling resign as a member of the Board.

Appointment of Interim Chief Executive Officer

On May 4, 2026, the Board appointed Terrie Kellmeyer,

PhD as the Company’s Interim Chief Executive Officer. Dr. Kellmeyer possesses over 30 years of experience in the pharmaceutical

industry and has held executive leadership positions in Clinical Development, Regulatory Affairs, Clinical Operations, and Medical Affairs

across multiple therapeutic areas. Prior to her appointment, she was the Senior Vice President, Clinical Development of the Company from

November 2023 to May 2025 and has continued to work with the Company as a Senior Advisor since that date. Dr. Kellmeyer has also been

acting as Executive Vice President, Regulatory Affairs at Aardvark Therapeutics since May 2025. Prior to joining Anavex, Dr. Kellmeyer

held strategic leadership positions, including Group Vice President of Clinical Development at Acer Therapeutics from August 2021 to November

2023, Head of Global Regulatory Affairs at Madrigal Pharmaceuticals from July 2019 to August 2021 and positions of increasing responsibility

at Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe. Dr. Kellmeyer also served as a consultant to Tunnell Consulting from

August 2022 to May 2026 and to i2o Therapeutics from July 2025 to December 2025. Dr. Kellmeyer received her BS degree in Biotechnology

from Rochester Institute of Technology, a PhD in Cell and Molecular Biology from SUNY Syracuse and did a Post-Doctoral Fellowship at the

University of Rochester.

In connection with Dr. Kellmeyer’s appointment,

her annual base salary was set at $500,000 and her annual bonus is anticipated to be 30% of her base salary. Pursuant to the terms of

her employment agreement, Dr. Kellmeyer will be paid a one-time cash signing bonus of $150,000 and will be awarded 200,000 stock options

at a meeting of the Company’s Compensation Committee as soon as reasonably practicable following her start date.

There are no family relationships between Dr. Kellmeyer

and any Company director or executive officer, and no arrangements or understandings between Dr. Kellmeyer and any other person pursuant

to which she was selected as an officer. There have been no transactions, and there are no currently proposed transactions, to which the

Company was or is a participant and in which Dr. Kellmeyer had or is to have a direct or indirect material interest that would require

disclosure pursuant to Item 404(a) of Regulation S-K.

A copy of the press release issued by the Company on

May 6, 2026, announcing the appointment of Dr. Kellmeyer is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1

Press Release dated May 6, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

ANAVEX LIFE SCIENCES CORP.

/s/ Sandra Boenisch

Name: Sandra Boenisch, CPA, CGA

Title: Principal Financial Officer, Treasurer

Date: May 6, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7613_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Anavex

Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief

Executive Officer

NEW

YORK, NY, May 6, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage

biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia,

neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders,

today announced that its Board of Directors has appointed the Company’s former Senior Vice President of Clinical Development and

current Senior Advisor, Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. These appointments follow the departure of

President and Chief Executive Officer Christopher Missling, PhD, MS, MBA, from the Company on April 30, 2026, and a request for his resignation

from the Board of Directors. Dr. Kellmeyer will lead the Company’s next phase of growth that aligns

with its strategic initiatives in enhancing the clinical development programs of the Company’s current portfolio.

“The

Board has the utmost confidence in Dr. Kellmeyer’s ability to drive our clinical programs forward,” said Dr. Ma. “Terrie

has extensive experience in senior leadership roles in the biotech and therapeutics space along with vast knowledge of our portfolio.

We believe her expertise in clinical development, regulatory and medical affairs, and quality assurance makes her the right partner to

advance our pipeline while working closely with both the FDA and the EMA.”

Dr.

Terrie Kellmeyer is a seasoned pharmaceutical executive with nearly three decades of experience across the full spectrum of drug development.

Dr. Kellmeyer has served as the Department Head for Global Regulatory Affairs, Clinical Development, Clinical Operations, Safety, Quality

Assurance and Medical Affairs at numerous healthcare companies over the last 30 years. Dr. Kellmeyer is a proven strategic leader, which

is supported by her track record of leading successful regulatory submissions resulting in multiple FDA and EMA approvals.

“I

look forward to executing and refining Anavex’s clinical, regulatory and operational strategy and working closing with the regulatory

authorities that will help advance the development of our compounds,” stated Dr. Kellmeyer. “We believe in our core mission

in developing innovative oral therapies for individuals living with neurological disorders and central nervous system diseases. With

a strong cash balance and no long-term debt, we will continue to focus on our lead candidate, oral blarcamesine,

in early Alzheimer’s disease, and begin to build out the appropriate team while creating long-term shareholder value.”

The

Company expects to file a Form 12b-25 to extend the filing date of its Quarterly Report on Form 10-Q for the quarter ended March 31,

2026, as it is currently not expected to meet the due date for such report under the rules of the Securities and Exchange Commission

(the “SEC”). The Company intends to host a conference call and webcast that will provide further information regarding its

second quarter 2026 financial results and the filing of its Form 10-Q at a later date.

About

Anavex Life Sciences Corp.

Anavex

Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics

for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com.

Forward-Looking

Statements

in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions

based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially

from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent

Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements,

which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and

Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the

date hereof.

Investor

Relations & Media Contact:

SCR

Partners, LLC

Alex

Arzeno

Tel:

203-550-3972

Email:

alex@scr-ir.com

Tripp

Sullivan

Tel:

615-942-7077

Email:

tsullivan@scr-ir.com

Company

Contact:

Sandra

Boenisch

Principal

Financial Officer

Anavex

Life Sciences Corp.

Tel:

1-844-689-3939

Email:

ir@anavexcorp.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity File Number

001-37606

Entity Registrant Name

ANAVEX LIFE SCIENCES CORP.

Entity Central Index Key

0001314052

Entity Tax Identification Number

98-0608404

Entity Incorporation, State or Country Code

Entity Address, Address Line One

630 5th Avenue

Entity Address, City or Town

20th Floor

Entity Address, State or Province

Entity Address, Postal Zip Code

10111

City Area Code

844

Local Phone Number

689-3939

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

AVXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration